Combinatorial pharmacophore modeling of multidrug and toxin extrusion transporter 1 inhibitors: A theoretical perspective for understanding multiple inhibitory mechanisms

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Xu, Yuan ^a   Liu, Xian ^a   Wang, Yulan ^a   Zhou, Nannan ^a   Peng, Jianlong ^a   Gong, Likun ^a   Ren, Jing ^a   Luo, Cheng ^a   Luo, Xiaomin ^a   Jiang, Hualiang ^a,b   Chen, Kaixian ^a,b   Zheng, Mingyue ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHANGHAITECH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; ORGANIC CATION TRANSPORTER;

ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; COMBINATORIAL CHEMISTRY; METABOLISM; MOLECULAR DOCKING; MOLECULAR MODEL; MOLECULAR WEIGHT;

COMBINATORIAL CHEMISTRY TECHNIQUES; LIGANDS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR WEIGHT; ORGANIC CATION TRANSPORT PROTEINS;

EID: 84940834899     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13684     Document Type: Review

References (26)

1. Giacomini, K. M. et al. Membrane transporters in drug development. Nat. Rev. Drug Discovery 9, 215-236 (2010).
2. Otsuka, M. et al. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Nat.l Acad. Sci. USA 102, 17923-17928 (2005).
3. Masuda, S. et al. Identification and functional characterization of a new human kidney-specific H cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol. 17, 2127-2135 (2006).
4. Morrissey, K. et al. The UCSF-FDA TransPortal: a public drug transporter database. Clin. Pharmacol. Ther. 92, 545-546 (2012).
5. Tanihara, Y. et al. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+organic cation antiporters. Biochem. Pharmacol. 74, 359-371 (2007).
6. Nakamura, T., Yonezawa, A., Hashimoto, S., Katsura, T. & Inui, K.-I. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem. Pharmacol. 80, 1762-1767 (2010).
7. Ito, S. et al. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J. Pharmacol. Exp. Ther. 340, 393-403 (2012).
8. Astorga, B., Ekins, S., Morales, M. & Wright, S. H. Molecular Determinants of Ligand Selectivity for the Human Multidrug and Toxin Extruder Proteins MATE1 and MATE2-k. J. Pharmacol. Exp. Ther. 341, 743-755 (2012).
9. Wittwer, M. B. et al. Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling. J. Med. Chem. 56, 781-795 (2013).
10. Xu, Y. et al. Combinatorial Pharmacophore Modeling of Organic Cation Transporter 2 (OCT2) Inhibitors: Insights into Multiple Inhibitory Mechanisms. Mol. Pharm. 10, 4611-4619 (2013).
11. Martinez-Guerrero, L. J. & Wright, S. H. Substrate-Dependent Inhibition of Human MATE1 by Cationic Ionic Liquids. J. Pharmacol. Exp. Ther. 346, 495-503 (2013).
12. Tanaka, Y. et al. Structural basis for the drug extrusion mechanism by a MATE multidrug transporter. Nature 496, 247-251 (2013).
13. Singh, S. K., Piscitelli, C. L., Yamashita, A. & Gouaux, E. A competitive inhibitor traps LeuT in an open-to-out conformation. Science 322, 1655-1661 (2008).
14. Konig, J., Zolk, O., Singer, K., Hoffmann, C. & Fromm, M. F. Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br. J. Pharmacol. 163, 546-555 (2011).
15. Yonezawa, A. & Inui, K. i. Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br. J. Pharmacol. 164, 1817-1825 (2011).
16. Zamek-Gliszczynski, M. J., Hoffmaster, K. A., Tweedie, D. J., Giacomini, K. M. & Hillgren, K. M. Highlights from the International Transporter Consortium Second Workshop. Clin. Pharmacol. Ther. 92, 553-556 (2012).
17. Motohashi, H. & Inui, K.-I. Multidrug and toxin extrusion family SLC47: Physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K. Mol. Aspects Med. 34, 661-668 (2013).
18. Kido, Y., Matsson, P. & Giacomini, K. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J. Med. Chem. 54, 4548-4558 (2011).
19. Dixon, S. L. et al. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput. Aided Mol. Des. 20, 647-671 (2006).
20. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J Mol. Biol. 215, 403-410 (1990).
21. He, X. et al. Structure of a cation-bound multidrug and toxic compound extrusion transporter. Nature 467, 991-994 (2010).
22. Sali, A. & Blundell, T. Comparative protein modelling by satisfaction of spatial restraints. Protein structure by distance analysis 64, C86 (1994).
23. Arnold, K., Bordoli, L., Kopp, J. & Schwede, T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22, 195-201 (2006).
24. Benkert, P., Tosatto, S. C. & Schomburg, D. QMEAN: A comprehensive scoring function for model quality assessment. Proteins 71, 261-277 (2008).
25. Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26, 283-291 (1993).
26. Halgren, T. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47, 1750-1759 (2004).